相关实验视频

Updated: May 3, 2026

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

针对动脉样硬化症的疫苗的工程仿真PCSK9

Špela Malenšek^1,2, Duško Lainšček^1,3, Hana Esih^1,2

¹Department of Synthetic Biology and Immunology, National Institute of Chemistry, 1000 Ljubljana, Slovenia.

Molecular therapy. Methods & clinical development

|August 18, 2025

概括

一种针对蛋白转化酶9 (PCSK9) 的新型化学疫苗有效降低了小鼠的胆固醇和动脉样硬化. 这种方法克服了免疫耐受性,为预防心血管疾病提供了一个有希望的长期战略.

科学领域:

免疫学免疫学免疫学
心血管科学心血管科学
疫苗开发疫苗开发

背景情况:

心血管疾病,特别是动脉样硬化,是全球主要的死亡原因.
降低血清低密度脂蛋白胆固醇 (LDL-C) 对于降低心血管风险至关重要.
向蛋白转化酶9 (PCSK9) 是一个有效的策略,目前的方法包括基因组编辑和单克隆抗体.

研究的目的:

开发一种针对PCSK9的新型疫苗策略,以克服免疫性和B细胞耐受性的挑战.
创建一种仿真PCSK9疫苗,可以引起强烈的幽默性免疫反应,同时最大限度地减少T细胞对自我抗原的反应.
在动脉样硬化小鼠模型中评估这种仿真疫苗的长期疗效.

主要方法:

设计和开发一种仿真PCSK9结构,保持表面表位,但缺乏天然T细胞表位.
用仿真PCSK9结构对小鼠进行疫苗接种.
评估幽默免疫 (PCSK9特异性抗体) 和T细胞反应性.
在已建立的动脉样硬化小鼠模型中评估治疗效果,测量循环PCSK9,胆固醇水平和大动脉样硬化负担.

主要成果:

仿真PCSK9疫苗成功诱导PCSK9特异性抗体,与人类疫苗相比,T细胞反应性降低.
在动脉样硬化模型中,接种疫苗导致循环PCSK9和胆固醇水平持续降低超过20周.
观察到大动脉内的动脉样硬化疾病负担显著减少,表明治疗改善.

结论:

一种合理设计的仿真PCSK9疫苗可以克服免疫耐受性,并产生强大的幽默免疫反应.
这种疫苗策略通过向内源性PCSK9,为动脉样硬化提供了一个有希望的,长期的治疗方法.
该研究提供了设计针对自我抗原的疫苗的概念证明,用于治疗慢性疾病.

关键词:

ApoE−/−小鼠的使用情况.这是PCSK9疫苗.T细胞细胞毒性 T细胞细胞毒性动脉样硬化动脉样硬化自生疫苗疫苗自生疫苗超高胆固醇血症是一种高胆固醇血症.塑体疫苗疫苗的使用情况蛋白质设计蛋白质设计

更多相关视频

Adeno-Associated Virus-Mediated Delivery of CRISPR for Cardiac Gene Editing in Mice

Adeno-Associated Virus-Mediated Delivery of CRISPR for Cardiac Gene Editing in Mice

Published on: August 2, 2018

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

相关概念视频

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...